Posted on 422
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA
® (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
“BRUKINSA is a highly selective BTK inhibitor designed to provide deep and durable response for patients with hematologic malignancies while reducing the frequency of certain side effects. With today’s approval, we are looking forward to bringing this potentially best-in-class BTK inhibitor to Canadians affected by WM,” said Josh Neiman, Chief Commercial Officer for North America and Europe at BeiGene. “We are committed to working to ensure access for patients in Canada and to making BRUKINSA available to patients in more markets worldwide.”
Press release content from Business Wire. The AP news staff was not involved in its creation.
Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
March 2, 2021 GMT
CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) Mar 2, 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA ® (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
“BRUKINSA is a highly selective BTK inhibitor designed to provide deep and durable response for patients with hematologic malignancies while reducing the frequency of certain side effects. With today’s approval, we are looking forward to bringing this potentially best-in-class BTK inhibitor to Canadians affected by WM,” said Josh Neiman, Chief Commercial Officer for North America and Euro
E-Mail
The use of the polymeric flame retardant PolyFR in eco-friendly foam plastic building insulation may be harmful to human health and the environment, according to a new commentary in
Environmental Science & Technology. The authors analysis identifies several points during the lifecycle of foam insulation that may expose workers, communities, and ecosystems to PolyFR and its potentially toxic breakdown products.
With the climate crisis fueling demand for energy-efficient insulation, the production of PolyFR is increasing rapidly. That s because this flame retardant is added to all foam plastic building insulation in North America to comply with flammability codes, replacing the flame retardant hexabromocyclododecane that has been globally phased out due to its toxicity and persistence. PolyFR is commonly assumed to be safe. However, the authors question that assumption.